 TEL AVIV, Israel, Dec. 07, 2020 GLOBE NEWSWIRE -- VBL Therapeutics Nasdaq: VBLT, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that the Companys Chairman of the Board, Dr. Bennett Shapiro, the CEO, Prof. Dror Harats and additional Company board members and senior management, made open-market purchases of approximately 200K shares of VBLT, between November 24 and December 3, 2020. 